Bacterial vaginosis: a primer for clinicians

References

• Morris M, Nicoll A, Simms I, et al. Bacterial vaginosis: a public health review. BJOG. 2001;108:439.
   Google Scholar
• Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey date. Obstet Gynecol. 2007;109:114–120.
   PubMed Web of Science ®Google Scholar
• Murphy K, Mitchell CM. The interplay of host immunity, environment and the risk of bacterial vaginosis and associated reproductive health outcomes. J Infect Dis. 2016;214(suppl 1):S29–S35.
   PubMed Web of Science ®Google Scholar
• Onderdonk AB, Delaney ML, Fichorova RN. The human microbiome during bacterial vaginosis. Clin Microbiol Rev. 2016;29(2):223–238.
   PubMed Web of Science ®Google Scholar
• Jung HS, Ehlers MM, Lombaard H, et al. Etiology of bacterial vaginosis and polymicrobial biofilm formation. Crit Rev Microbiol. 2017;43(6):651–667.
   PubMed Web of Science ®Google Scholar
• Campisciano G, Zanotta N, Licastro D, et al. In vivo microbiome and associated immune markers: new insights into the pathogenesis of vaginal dysbiosis. Sci Rep. 2018;8(1):2307.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Kimble T, Herold B, et al. Bacterial vaginosis and subclinical markers of genital tract inflammation and mucosal immunity. AIDS Res Hum Retroviruses. 2015;31(11):1139–1152.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Subramanian C, Foxman B, et al. Mixed vaginitis—more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013;15(2):104–108.
   PubMed Web of Science ®Google Scholar
• Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011;118(5):533–549.
   Google Scholar
• Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2015;91:42–50.
   Web of Science ®Google Scholar
• Bagnall P, Rizzolo D. Bacterial vaginosis: a practical review. JAAPA. 2017;30(12):15–21.
   PubMedGoogle Scholar
• Esber A, Vicetti Miguel RD, Cherpes TL, et al. Risk of bacterial vaginosis among women with herpes simplex virus type 2 infection: a systematic review and meta-analysis. J Infect Dis. 2015;212(1):8–17.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Bacterial Vaginosis – CDC Fact Sheet. Atlanta, GA: CDC; 2017. [ cited 2018 Oct 3] Available from: https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm
   Google Scholar
• Ranjit E, Raghubanshi BR, Maskey S, et al. Prevalence of bacterial vaginosis and its association with risk factors among nonpregnant women: a hospital based study. Int J Microbiol. 2018;2018:8349601.
   PubMedGoogle Scholar
• Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014;160(Pt 10):2272–2282.
   PubMed Web of Science ®Google Scholar
• Van de Wijgert JHHM, Jespers V. The global health impact of vaginal dysbiosis. Res Microbiol. 2017;168(9–10):859–864.
   PubMed Web of Science ®Google Scholar
• Wilson JD, Lee RA, Balen AH, et al. Bacterial vaginal flora in relation to changing oestrogen levels. Int J STD AIDS. 2007;18(5):308–311.
   PubMed Web of Science ®Google Scholar
• Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055.
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777–786.
   PubMed Web of Science ®Google Scholar
• Power ML, Quaglieri C, Schulkin J. Reproductive microbiomes: a new thread in the microbial network. Reprod Sci. 2017;24(11):1482–1492.
   PubMed Web of Science ®Google Scholar
• Schellenberg JJ, Patterson MH, Hill JE. Gardnerella vaginalis diversity and ecology in relation to vaginal symptoms. Res Microbiol. 2017;168(9–10):837–844.
   PubMed Web of Science ®Google Scholar
• Janulaitiene M, Paliulyte V, Grinceviciene S, et al. Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis. BMC Infect Dis. 2017;17(1):394.
   PubMed Web of Science ®Google Scholar
• Tachedjian G, O’Hanion DE, Ravel J. The implausible “in vivo” role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. Microbiome. 2018;6(1):29.
   PubMed Web of Science ®Google Scholar
• Wolrath H, Forsum U, Larsson PG, et al. Analysis of bacterial vaginosis-related amines in vaginal fluid by gas chromatography and mass spectrometry. J Clin Microbiol. 2001;39(11):4026–4031.
   PubMed Web of Science ®Google Scholar
• Hodiwala AB, Koli A. Bacterial vaginosis. Int J Curr Microbiol App Sci. 2015;4(6):530–538.
   Google Scholar
• Cook RL, Reid G, Pond DG, et al. Clue cells in bacterial vaginosis: immunofluorescent identification of the adherent gram-negative bacteria as Gardnerella vaginalis. J Infect Dis. 1989;160(3):490–496.
   PubMed Web of Science ®Google Scholar
• Amegashie CP, Gilbert NM, Peipert JF, et al. Relationship between Nugent score and vaginal epithelial exfoliation. PLoS One. 2017;12(5):e0177797.
   PubMed Web of Science ®Google Scholar
• Brogden KA, Guthmiller JM, eds. Polymicrobial Diseases. Washington, DC: ASM Press; 2002.
   Google Scholar
• Swidsinski A, Loening-Baucke V, Mendling W, et al. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol Histopathol. 2014;29(5):567–587.
   PubMed Web of Science ®Google Scholar
• Castro J, Cerca N. BV and non-BV associated Gardnerella vaginalis establish similar synergistic interactions with other BV-associated microorganisms in dual-species biofilms. Anaerobe. 2015;36:56–59.
   PubMed Web of Science ®Google Scholar
• Hay P. Bacterial vaginosis. F1000Res. 2017;6:1761.
   PubMedGoogle Scholar
• Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426-1435.
   Web of Science ®Google Scholar
• Nelson DE, Dong Q, Van der Pol B, et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One. 2012;7(5):e36298.
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Walker SM, Vodstrcil LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis. 2014;209(10):1562–1572.
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Morton AN, Garland SM, et al. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005;106(1):105–114.
   PubMed Web of Science ®Google Scholar
• Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis—a marginal structural modeling analysis. Am J Epidemiol. 2008;168(2):188-196.
   Web of Science ®Google Scholar
• Klebanoff MA, Nansel TR, Brotman RM, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Trans Dis. 2010;37(2):94–99.
   PubMed Web of Science ®Google Scholar
• Babu G, Singaravelu BG, Srikumar R, et al. Comparative study on the vaginal flora and incidence of asymptomatic vaginosis among healthy women and in women with infertility problems of reproductive age. J Clin Diagn Res. 2017;11(8):DC18–DC22.
   PubMed Web of Science ®Google Scholar
• Neggers YH, Nansel TR, Andrews WW, et al. Dietary intake of selected nutrients affects bacterial vaginosis in women. J Nutr. 2007;137(9):2128–2133.
   PubMed Web of Science ®Google Scholar
• Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004;104(2):267–272.
   PubMed Web of Science ®Google Scholar
• Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22.
   PubMed Web of Science ®Google Scholar
• Klebanoff MA, Huath JC, MacPherson CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol. 2004;190(2):363–370.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis. 2006;193(5):617–624.
   PubMed Web of Science ®Google Scholar
• Flynn CA, Helwig AL, Meureer LN. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. J Fam Pract. 1999;48(11):885–892.
   PubMed Web of Science ®Google Scholar
• Klebanoff MA, Hillier SL, Nugent RP, et al. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol. 2005;192(2):470–477.
   PubMed Web of Science ®Google Scholar
• Andrews WW, Klebanoff MA, Thom EA, et al. Midpregnancy genitourinary tract infection with Chlamydia trachomatis: association with subsequent preterm delivery in women with bacterial vaginosis and Trichomonas vaginalis. Am J Obstet Gynecol. 2006;194(2):493–500.
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. Infect Dis Obstet Gynecol. 1995;3(4):149–157.
   PubMedGoogle Scholar
• Cohen C, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9:e1001251.
   PubMed Web of Science ®Google Scholar
• Balkus JE, Richardson BA, Rabe LK, et al. Bacterial vaginosis and the risk of Trichomonas vaginalis acquisition among HIV-1-negative women. Sex Trans Dis. 2014;41(2):123–128.
   PubMed Web of Science ®Google Scholar
• Cherpes TL, Megyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis. 2003;37(3):319–325.
   PubMed Web of Science ®Google Scholar
• Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis. 2003;36(5):663–668.
   PubMed Web of Science ®Google Scholar
• Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104(4):761–769.
   PubMed Web of Science ®Google Scholar
• Gillet E, Meys JF, Verstraelen H, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One. 2012;7(10):e45201.
   PubMed Web of Science ®Google Scholar
• Risser WL, Risser JM, Risser AL. Current perspectives in the USA on the diagnosis and treatment of pelvic inflammatory disease in adolescents. Adolesc Health Med Ther. 2017;8:87–94.
   PubMed Web of Science ®Google Scholar
• Tam MT, Yungbluth M, Myles T. Gram stain methods shows better sensitivity than clinical criteria for detection of bacterial vaginosis in surveillance of pregnant, low-income women in a clinical setting. Infect Dis Obstet Gynecol. 1998;6(5):204–208.
   PubMedGoogle Scholar
• Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR–03):1–137.
   PubMed Web of Science ®Google Scholar
• Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158(4):819-828.
   Web of Science ®Google Scholar
• Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190(4):1004–1010.
   PubMed Web of Science ®Google Scholar
• Greene JF 3rd, Kuehl TJ, Allen SR. The papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy. Am J Obstet Gynecol. 2000;182(5):1048–1049.
   PubMed Web of Science ®Google Scholar
• Cartwright CP, Lembke BD, Ramachandran K, et al. Comparison of nucleic acid amplification assays with BD Affirm VPIII for diagnosis in vaginitis in symptomatic women. J Clin Microbiol. 2013;5(11):3694–3699.
   Web of Science ®Google Scholar
• Becton, Dickinson and Company. BD Diagnostics Affirm brochure; December 2010. Sparks, MD: BD Diagnostics. Available from https://www.bd.com/Documents/bd-legacy/brochures/molecular-diagnostics/BD_Affirm-VPIII-Brochure-PE_TR.pdf.
   Google Scholar
• Bradshaw CS, Morton AN, Garland SM, et al. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol. 2005;43(3):1304–1308.
   PubMed Web of Science ®Google Scholar
• Madhivanan P, Krupp K, Li T, et al. Performance of BVBlue rapid test in detecting bacterial vaginosis among women in Mysore, India. Infect Dis Obstet Gynecol. 2014;2014:908313.
   PubMedGoogle Scholar
• Van Der Pol B. Profile of the triplex assay for detection of chlamydia, gonorrhea and trichomonas using the BD MAX™ System. Expert Rev Mol Diagn. 2017;17(6):539–547.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964.
   PubMedGoogle Scholar
• Crowley T, Low N, Turner A, et al. Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomized controlled trial. BJOG. 2001;108(4):396–402.
   PubMed Web of Science ®Google Scholar
• Larsson PG, Carlsson B. Dose pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis? Infect Dis Obstet Gynecol. 2002;10(3):133–140.
   PubMedGoogle Scholar
• Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. BJOG. 2004;111(9):982–988.
   Google Scholar
• Penney GC, Ghomspon M, Norman J, et al. A randomized comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol. 1998;105(6):599–604.
   PubMedGoogle Scholar
• Balkus JE, Manhart LE, Lee J, et al. Periodic presumptive treatment for vaginal infections may reduce the incidence of sexually transmitted bacterial infections. J Infect Dis. 2016;213(12):1932–1937.
   PubMed Web of Science ®Google Scholar
• Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610–4617.
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196(6):517.e1-e6.
   PubMed Web of Science ®Google Scholar
• Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):375–390.
   PubMed Web of Science ®Google Scholar
• Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. 1988;319(15):972–978.
   PubMed Web of Science ®Google Scholar
• Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an updated review for the US Preventive Services Task Force. Ann Intern Med. 2008;148(3):220–233.
   PubMed Web of Science ®Google Scholar
• Yudin MH, Money DM. No. 211—screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can. 2017;39(8):e184–e191.
   PubMed Web of Science ®Google Scholar
• Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333(26):1732–1736.
   PubMed Web of Science ®Google Scholar
• McDonald HM, O’Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomized, placebo controlled trial. Br J Obstet Gynaecol. 1997;104(12):1391–1397.
   PubMedGoogle Scholar
• Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994;171(2):345–347.
   PubMed Web of Science ®Google Scholar
• Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomized placebo-controlled double-blind trial. Br J Obstet Gynaecol. 1999;106(7):652–657.
   PubMedGoogle Scholar
• Sawaya GF, Grady D, Kerlikowske K, et al. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996;87(5):884–890.
   Web of Science ®Google Scholar
• Brocklehurst P, Gordon A, Heatley E, et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013 Jan 31;CD000262.
   PubMed Web of Science ®Google Scholar
• Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol. 2003;188(3):752–758.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Bacterial Vaginosis. Atlanta, GA: CDC; 2015. [cited 2018 Oct 2] Available from https://www.cdc.gov/std/tg2015/bv.htm
   Google Scholar
• Metronidazole. Micromedex Solutions. Ann Arbor, MI: Truven Health Analytics, Inc. [cited 2018 Oct 3] Available from: http://www.micromedexsolutions.com
   Google Scholar
• Clindamycin Cream. Micromedex Solutions. Ann Arbor, MI: Truven Health Analytics, Inc. [cited 2018 Oct 3] Available from: http://www.micromedexsolutions.com
   Google Scholar
• Tinidazole. Micromedex Solutions. Ann Arbor, MI: Truven Health Analytics, Inc. [cited 2018 Oct 3] Available from: http://www.micromedexsolutions.com
   Google Scholar
• Secnidazole. Micromedex Solutions. Ann Arbor, MI: Truven Health Analytics, Inc. [cited 2018 Oct 3] Available from: http://www.micromedexsolutions.com
   Google Scholar
• Rathe M, Müller K, Sangild PT, et al. Clinical applications of bovine colostrum therapy: a systematic review. Nutr Rev. 2014;72(4):237–254.
   PubMed Web of Science ®Google Scholar
• Faro S, Skokos CK; Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol. 2005;13(3):155–160.
   PubMedGoogle Scholar
• Schwebke JR, Marrazzo J, Beelen AP, et al. A phase 3, multicenter, randomized double-blind vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis. 2015;42(7):376–381.
   PubMed Web of Science ®Google Scholar
• Bohbot JM, Vicaut E, Fagnen D, et al. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomized phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol. 2010;2010:705692.
   PubMedGoogle Scholar
• Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in nonpregnant women. Cochrane Database Syst Rev. 2009 Jul8;(3):CD006055.
   Google Scholar
• Metrogel Vaginal [prescribing information]. Northridge, CA: 3M Pharmaceuticals; 2006.
   Google Scholar
• Tindamax [prescribing information]. San Antonio, TX: Mission Pharmacal Company; 2007.
   Google Scholar
• Schwebke JR, Demond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2011;204(3):211.e1–e6.
   PubMed Web of Science ®Google Scholar
• Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur J Obstet Gynecol Reprod Biol. 2003;109(1):67–71.
   PubMed Web of Science ®Google Scholar
• Livengood CH, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis. Obstet Gynecol. 2007;110(2):302–309.
   PubMed Web of Science ®Google Scholar
• Raja IM, Basavareddy A, Mukherjee D, et al. Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis. Indian J Pharmacol. 2016;48(6):654–658.
   PubMed Web of Science ®Google Scholar
• Solosec [prescribing information]. Newark, NJ: Symbiomix Therapeutics, LLC; 2017.
   Google Scholar
• Gillis JC, Wiseman LR. Secnidazole, a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996;51(4):621–638.
   PubMed Web of Science ®Google Scholar
• Nunez JT, Gomez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2005;88(3):281–285.
   PubMed Web of Science ®Google Scholar
• Petrina MAB, Cosentino LA, Rabe LK, et al. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115–119.
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Adetoro N. Two phase 1, open-label, single-dose, randomized, crossover studies to assess the pharmacokinetics, safety, and tolerability of orally administered granules of secnidazole (2 g) in healthy female volunteers under different administration conditions. Clin Pharmacol Drug Dev. 2018;7(5):543-553.
   Web of Science ®Google Scholar
• Schwebke JR, Morgan FG Jr, Koltun W, et al. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678e1-678e9.
   Google Scholar
• Darpo B, Xue H, Adetoro N, et al. Thorough QT/QTc evaluation of the cardiac safety of secnidazole at therapeutic and supratherapeutic doses in healthy individuals. J Clin Pharmacol. 2018;58(3):286-293.
   Web of Science ®Google Scholar
• Pentikis HS, Adetor N, Braun CJ. Lack of a pharmacokinetic interaction between SYM-1219 granules containing 2 grams of secnidazole and a combined oral contraceptive in a phase 1, randomized, open-label study in healthy female volunteers. Adv Ther. 2017;33(12):2229–2241.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). In: Guidance for Industry: Bacterial Vaginosis: Developing Drugs for Treatment. Silver Spring, MD: FDA; 2016. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/UCM510948.pdf
   Google Scholar
• Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017;130(2):379–386.
   PubMed Web of Science ®Google Scholar
• Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49(6):897–903.
   PubMed Web of Science ®Google Scholar
• Bartley JB, Ferris DG, Allmond LM, et al. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488–491.
   PubMed Web of Science ®Google Scholar
• Mur Pérez AM, Mateo Segura Z, Ramírez Domínguez N, Vela Condón P. Use of probiotics in bacterial vaginosis. Semergen. 2017;43(5):394–398. [Article in Spanish].
   PubMedGoogle Scholar
• Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79–86.
   PubMed Web of Science ®Google Scholar
• Senok AC, Verstraelen H, Temmerman M, et al. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009 Oct7;(4):CD006289.
   Google Scholar
• Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017;11:CD010496.
   PubMed Web of Science ®Google Scholar
• Pino A, Giunta G, Randazzo CL, et al. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb Ecol Health Dis. 2017;28(1):1357417.
   PubMedGoogle Scholar
• Otsuki K, Imai N. Effects of lactoferrin in 6 patients with refractory bacterial vaginosis. Biochem Cell Biol. 2017;95(1):31–33.
   PubMed Web of Science ®Google Scholar
• Machado D, Castro J, Palmeira-de-Oliveira A, et al. Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol. 2015;6:1528.
   PubMed Web of Science ®Google Scholar
• Weissenbacher ER, Donders G, Unzeitig V, et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012;73(1):8–15.
   PubMed Web of Science ®Google Scholar
• Braga PC, Dal Sasso M, Culici M, et al. Inhibitory activity of thymol on native and mature Gardnerella vaginalis biofilms: in vitro study. Arzneimittelforschung. 2010;60(11):675–681.
   PubMed Web of Science ®Google Scholar
• Hymes SR, Randis TM, Sun TY, et al. DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis. 2013;207(10):1491–1497.
   PubMed Web of Science ®Google Scholar
• Hooven TA, Randis TM, Hymes SR, et al. Retrocyclin inhibits Gardnerella vaginalis biofilm formation and toxin activity. J Antimicrob Chemother. 2012;67(12):2870–2872.
   PubMed Web of Science ®Google Scholar
• Gottschick C, Deng ZL, Vital M, et al. Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary—clinical study and microbiota analysis. Microbiome. 2017;5(1):119.
   PubMed Web of Science ®Google Scholar
• Algburi A, Zhang Y, Weeks R, et al. Gemini cationic amphiphiles control biofilm formation by bacterial vaginosis pathogens. Antimicrob Agents Chemother. 2017;61(12):e00650–17.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. US National Library of Medicine. LactMed: a TOXNET database. [ cited 2018 Nov 9] Available from: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm
   Google Scholar
• Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283.
   PubMed Web of Science ®Google Scholar
• Xiao B, Niu X, Han N, et al. Predictive value of the composition of the vaginal microbiota in bacterial vaginosis, a dynamic study to identify recurrence-related flora. Sci Rep. 2015;6:26674.
   Web of Science ®Google Scholar
• Tosheva-Daskalova K, Strateva TV, Mitov IG, et al. Multiplex PCR detection of problematic pathogens of clinically heterogeneous bacterial vaginosis in Bulgarian women. Turk J Med Sci. 2017;47(5):1492–1499.
   PubMed Web of Science ®Google Scholar
• Ferreira CST, Donders GG, Parada CMGL, et al. Treatment failure of bacterial vaginosis is not associated with higher loads of Atopobium vaginae and Gardnerella vaginalis. J Med Microbiol. 2017;66(8):1217–1224.
   PubMed Web of Science ®Google Scholar
• McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197(10):1361–1368.
   PubMed Web of Science ®Google Scholar
• McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J Infect Dis. 2015;211(12):1875–1882.
   PubMed Web of Science ®Google Scholar
• Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013;8(9):e74378.
   PubMed Web of Science ®Google Scholar
• Payne SC, Cromer PR, Stanek MK, et al. Evidence of African-American women’s frustrations with chronic recurrent bacterial vaginosis. J Am Acad Nurse Pract. 2010;22(2):101–108.
   PubMed Web of Science ®Google Scholar
• Bilardi J, Walker S, McNair R, et al. Women’s management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016;11(3):e0151794.
   PubMed Web of Science ®Google Scholar
• Keane FE, Maw R, Pritchard C, et al. Methods employed by genitourinary medicine clinics in the United Kingdom to diagnose bacterial vaginosis. Sex Trans Infect. 2005;81(2):155–157.
   PubMed Web of Science ®Google Scholar
• Barnes P, Viera R, Harwood J, et al. Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care. Br J Gen Pract. 2017;67(665):e824–e829.
   PubMed Web of Science ®Google Scholar